Table 2.
Summary of Subject Demographics
| Characteristics | Meloxicam IV 30 mg (n=283) |
Placebo (n=96) |
|---|---|---|
| Age (years) – mean ± SD | 59.7 ± 10.90 | 59.5 ± 12.06 |
| Age ≥65 years, n (%) | 109 (38.5) | 37 (38.5) |
| Sex, n (%) | ||
| Male | 105 (37.1) | 30 (31.3) |
| Female | 178 (62.9) | 66 (68.8) |
| Race, n (%) | ||
| White | 249 (88.0) | 86 (89.6) |
| Black or African American | 30 (10.6) | 6 (6.3) |
| Asian | 3 (1.1) | 3 (3.1) |
| Multiple | 1 (0.4) | 1 (1.0) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 30 (10.6) | 12 (12.5) |
| Neither Hispanic nor Latino | 253 (89.4) | 84 (87.5) |
| Baseline BMI (kg/m2) – mean ± SD | 30.2 ± 4.7 | 29.8 ± 4.8 |
| Surgery duration (hr) – mean ± SD | 1.3 ± 0.77 | 1.4 ± 0.95 |
| High risk, n (%) | 79 (27.9) | 26 (27.1) |
| Time (hr) from end of surgery to first dose – mean ± SD | 2.1 ± 1.47 | 2.2 ± 1.46 |
Abbreviations: BMI, body mass index; hr, hour; IV, intravenous; SD, standard deviation.